Abstract
Pyrroloquinoline quinone (PQQ) is a powerful neuroprotectant that specifically binds to brain NMDA receptors and inhibits excitotoxicity. Imaging this binding reaction in the brain remains a long sought goal in this field of study, and one of the primary challenges remaining is enabling soluble labeled PQQ to pass the blood–brain barrier (BBB). Previously, our group successfully labeled PQQ with Technetium-99m (99mTc), a metastable nuclear isomer used in radioactive isotope medical tests. In this work, we determined the specific binding of 99mTc-PQQ and NMDAR by radioligand receptor assay. Ebselen (EB) and MK-801 both effectively inhibited 99mTc-PQQ binding. We then investigated methods of opening the BBB using mannitol to enable entry to the brain by 99mTc-PQQ. Our results showed that 7.5 mL/kg of 20 % mannitol effectively opened the BBB and 20 min was the optimum treatment time. Competition studies showed that mannitol did not affect the specific binding between 99mTc-PQQ and NMDA receptors. Using this method, the amount of 99mTc-PQQ uptake and retention was increased most significantly in the hippocampus and cortex, and re-opening the BBB did not affect binding. Together, our results demonstrate that the use of mannitol to open the BBB may contribute significantly to improving image quality by increasing the uptake amount of a water-soluble agent in brain.
Similar content being viewed by others
References
Stites TE, Mitchell AE, Rucker RB (2000) Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr 130:719–727
McIntire WS (1998) Newly discovered redox cofactors: possible nutritional, medical, and pharmacological relevance to higher animals. Annu Rev Nutr 18:145–177
Davidson VL (2001) Pyrroloquinoline quinone (PQQ) from methanol dehydrogenase and tryptophan tryptophylquinone (TTQ) from methylamine dehydrogenase. Adv Protein Chem 58:95–140
Anthony C (2001) Pyrroloquinoline quinone (PQQ) and quinoprotein enzymes. Antioxid Redox Signal 3:757–774
Zhang P, Xu YP, Sun JX et al (2009) Protection of pyrroloquinoline quinone against methylmercury-induced neurotoxicity via reducing oxidative stress. Free Radical Res 43(3):224–233
Rucker R, Chowanadisai W, Nakano M (2009) Potential physiological importance of pyrroloquinoline quinone. Altern Med Rev 14(3):268–277
Ganapathy PS, White RE, Ha Y et al (2011) The role of N-methyl-d-aspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest Ophthalmol Vis Sci 52(8):5515–5524
Ohnuma T, Arai H (2011) Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35(1):29–39
Tsai GE, Lin PY (2010) Strategies to enhance N-methyl-d-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 16(5):522–537
Yang JH, Wada A, Yoshida K et al (2010) Brain-specific Phgdh deletion reveals a pivotal role for l-serine biosynthesis in controlling the level of d-serine, an N-methyl-d-aspartate receptor co-agonist, in adult brain. J Biol Chem 285(53):41380–41390
Frasca A, Aalbers M, Frigerio F et al (2011) Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity, neurobiology of disease. Neurobiol Dis 43(2):507–515
Sobrio F, Gilbert G, Perrio C et al (2010) PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development. Mini Rev Med Chem 10(9):870–886
Hansell C (2008) Nuclear medicine’s double hazard. Nonprolif Rev 15:185–208
Eckelman WC (2009) Unparalleled contribution of technetium-99m to medicine over 5 decades. JACC Cardiovasc Imaging 2:364–368
Kong YY, Zhou XQ, Cao GX et al (2010) Preparation of 99mTc-PQQ and preliminary biological evaluation for the NMDA receptor. J Radioanal Nucl Chem 286(1):93–101
Pardridge WM (2005) The blood-brain barrier: bottleneck is brain drug development. J Am Soc Exp Neuro Ther 2:3–14
Brown RC, Egleton RD, Davis TP (2004) Mannitol opening of the blood–brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Res 1014:221–227
Chi OZ, Hunter C, Liu X et al (2008) Effects of VEGF on the blood-brain barrier disruption caused by hyperosmolarity. Pharmacology 82:187–192
Reynolds IJ, Sharma TA (1999) The use of ligand binding in assays of NMDA receptor function. Methods Mol Biol 128:93–102
Acknowledgments
This work was supported by the National Natural Science Foundation of China (30770602) and the Natural Science Foundation of Jiangsu Province, China (BK2010157, BK2011167).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, X., Kong, Y., Cao, G. et al. Preliminary studies of 99mTc-PQQ-NMDAR binding and effect of specificity binding by mannitol. J Radioanal Nucl Chem 295, 335–343 (2013). https://doi.org/10.1007/s10967-012-1860-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-012-1860-5